The estimated Net Worth of Victor M Clavelli is at least $850 Тысяча dollars as of 15 December 2022. Mr Clavelli owns over 3,208 units of OptiNose Inc stock worth over $183,959 and over the last 5 years he sold OPTN stock worth over $82,090. In addition, he makes $584,202 as Chief Commercial Officer at OptiNose Inc.
Mr has made over 7 trades of the OptiNose Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 3,208 units of OPTN stock worth $5,422 on 15 December 2022.
The largest trade he's ever made was buying 34,000 units of OptiNose Inc stock on 20 May 2021 worth over $104,040. On average, Mr trades about 4,725 units every 49 days since 2020. As of 15 December 2022 he still owns at least 199,955 units of OptiNose Inc stock.
You can see the complete history of Mr Clavelli stock trades at the bottom of the page.
Victor M. Clavelli is the Chief Commercial Officer at OptiNose Inc.
As the Chief Commercial Officer of OptiNose Inc, the total compensation of Mr Clavelli at OptiNose Inc is $584,202. There are 8 executives at OptiNose Inc getting paid more, with Peter Miller having the highest compensation of $2,033,500.
Mr Clavelli is 48, he's been the Chief Commercial Officer of OptiNose Inc since . There are 12 older and 4 younger executives at OptiNose Inc. The oldest executive at OptiNose Inc is Sandra Helton, 70, who is the Independent Director.
Victor's mailing address filed with the SEC is C/O OPTINOSE, INC., 1020 STONY HILL ROAD, SUITE 300, YARDLEY, PA, 19067.
Over the last 19 years, insiders at OptiNose Inc have traded over $144,654,703 worth of OptiNose Inc stock and bought 116,688 units worth $814,936 . The most active insiders traders include Sriram Venkataraman, Capital Partners Ii Gp, Llc... и Rajat Rai. On average, OptiNose Inc executives and independent directors trade stock every 26 days with the average trade being worth of $106,645. The most recent stock trade was executed by Anthony J Krick on 17 July 2024, trading 6,845 units of OPTN stock currently worth $7,803.
optinose, inc., established in 2010 and headquartered in yardley, pennsylvania, is a publicly traded, global specialty pharmaceutical company focused on serving the needs of patients cared for by ent and allergy specialists. our team of kind, passionate, innovative people is building a new kind of organization without the encumbrances of a company with legacy systems and beliefs. we are unified by a shared mission: to improve lives. we do this while also creating great value for the healthcare system and great outcomes for our stakeholders. as innovators in every aspect of our work, we pursue faster and less costly product development, explore evolving commercial business models, and actively seek innovative ways to be more effective and efficient in all areas of the business. we operate with an overarching commitment to doing what is right. we are committed to working together as a team that chooses to live every day by core company values that guide our daily behaviors, creating a fo
OptiNose Inc executives and other stock owners filed with the SEC include: